Free Trial
OTCMKTS:PVCT

Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis

Provectus Biopharmaceuticals logo
$0.10 +0.00 (+0.20%)
As of 03/28/2025 03:57 PM Eastern

About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT)

Key Stats

Today's Range
$0.10
$0.10
50-Day Range
$0.09
$0.12
52-Week Range
$0.04
$0.20
Volume
325,757 shs
Average Volume
238,030 shs
Market Capitalization
$42.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Remove Ads
Receive PVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PVCT Stock News Headlines

Provectus announces $3M seed financing round for VisiRose
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Provectus announces the launch of VisiRose
Provectus Pharmaceuticals Aligns Leadership with Equity Grants
Provectus Pharmaceuticals to Reveal Key 2024 Updates
See More Headlines

PVCT Stock Analysis - Frequently Asked Questions

Provectus Biopharmaceuticals' stock was trading at $0.1201 at the beginning of 2025. Since then, PVCT stock has decreased by 16.6% and is now trading at $0.1002.
View the best growth stocks for 2025 here
.

Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), American Superconductor (AMSC), Cannabis Science (CBIS) and (DARA) (DARA).

Company Calendar

Today
3/28/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:PVCT
Previous Symbol
NYSEMKT:PVCT
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,100,000.00
Net Margins
-418.23%
Pretax Margin
-418.37%

Debt

Sales & Book Value

Annual Sales
$560,000.00
Price / Cash Flow
N/A
Book Value
($0.02) per share
Price / Book
-5.01

Miscellaneous

Free Float
366,484,000
Market Cap
$42.11 million
Optionable
Not Optionable
Beta
0.61
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (OTCMKTS:PVCT) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners